Literature DB >> 11716876

Continuing controversy over adjuvant therapy of pancreatic cancer.

R A Abrams1, K D Lillemoe, S Piantadosi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11716876     DOI： 10.1016/S0140-6736(01)06666-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  25 in total

1.  Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Authors:  Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-01       Impact factor: 7.038

Review 2.  Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.

Authors:  Daneng Li; Eileen M O'Reilly
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

Review 3.  Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal".

Authors:  Ross A Abrams
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  The role of radiotherapy in management of pancreatic cancer.

Authors:  Fen Wang; Parvesh Kumar
Journal:  J Gastrointest Oncol       Date:  2011-09

5.  Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.

Authors:  Andrew M McDonald; Caleb R Dulaney; Javier López-Araujo; James A Posey; Kimberly S Keene; John D Christein; Martin J Heslin; Tina E Wood; Rojymon Jacob
Journal:  J Gastrointest Cancer       Date:  2015-06

Review 6.  Proton therapy for pancreatic cancer.

Authors:  Romaine C Nichols; Soon Huh; Zuofeng Li; Michael Rutenberg
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

7.  Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancers.

Authors:  John S Moody; Stephen M Sawrie; Kevin R Kozak; John P Plastaras; George Howard; James A Bonner
Journal:  J Gastrointest Cancer       Date:  2009-03-18

8.  Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.

Authors:  Jona A Hattangadi; Theodore S Hong; Beow Y Yeap; Harvey J Mamon
Journal:  Cancer       Date:  2009-08-15       Impact factor: 6.860

Review 9.  Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.

Authors:  Lingling Du; Melissa DeFoe; Marianna B Ruzinova; Jeffrey R Olsen; Andrea Wang-Gillam
Journal:  Hematol Oncol Clin North Am       Date:  2015-05-30       Impact factor: 3.722

10.  Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Authors:  Charles C Hsu; Joseph M Herman; Michele M Corsini; Jordan M Winter; Matthew D Callister; Michael G Haddock; John L Cameron; Timothy M Pawlik; Richard D Schulick; Christopher L Wolfgang; Daniel A Laheru; Michael B Farnell; Michael J Swartz; Leonard L Gunderson; Robert C Miller
Journal:  Ann Surg Oncol       Date:  2010-01-20       Impact factor: 5.344
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.